[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201171043A1 - Композиции и способы длительной терапии с применением аминопиридинов - Google Patents

Композиции и способы длительной терапии с применением аминопиридинов

Info

Publication number
EA201171043A1
EA201171043A1 EA201171043A EA201171043A EA201171043A1 EA 201171043 A1 EA201171043 A1 EA 201171043A1 EA 201171043 A EA201171043 A EA 201171043A EA 201171043 A EA201171043 A EA 201171043A EA 201171043 A1 EA201171043 A1 EA 201171043A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aminopyridines
compositions
methods
long
term therapy
Prior art date
Application number
EA201171043A
Other languages
English (en)
Other versions
EA022755B1 (ru
Inventor
Эндрю Р. Блайт
Рон Коэн
Original Assignee
Акорда Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201171043(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Акорда Терапьютикс, Инк. filed Critical Акорда Терапьютикс, Инк.
Publication of EA201171043A1 publication Critical patent/EA201171043A1/ru
Publication of EA022755B1 publication Critical patent/EA022755B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящей заявке раскрыты способы и композиции, связанные с применением аминопиридинов, таких как 4-аминопиридин, для применения терапевтически эффективным способом у пациентов с демиелинизирующим заболеванием, таким как рассеянный склероз.
EA201171043A 2009-02-11 2010-02-11 Способы длительной терапии с применением аминопиридинов EA022755B1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15167909P 2009-02-11 2009-02-11
US25956309P 2009-11-09 2009-11-09
US28587209P 2009-12-11 2009-12-11
US28895309P 2009-12-22 2009-12-22
US29925910P 2010-01-28 2010-01-28
PCT/US2010/023970 WO2010093839A1 (en) 2009-02-11 2010-02-11 Compositions and methods for extended therapy with aminopyridines

Publications (2)

Publication Number Publication Date
EA201171043A1 true EA201171043A1 (ru) 2012-02-28
EA022755B1 EA022755B1 (ru) 2016-02-29

Family

ID=42562065

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171043A EA022755B1 (ru) 2009-02-11 2010-02-11 Способы длительной терапии с применением аминопиридинов

Country Status (22)

Country Link
US (3) US20120029035A1 (ru)
JP (1) JP2012517449A (ru)
KR (3) KR20120000560A (ru)
CN (2) CN101896182A (ru)
AR (1) AR075413A1 (ru)
AU (2) AU2010213663A1 (ru)
BR (2) BRPI1000030A2 (ru)
CA (1) CA2751581A1 (ru)
CL (1) CL2011001927A1 (ru)
CO (1) CO6440534A2 (ru)
EA (1) EA022755B1 (ru)
EC (1) ECSP11011311A (ru)
IL (1) IL214500A0 (ru)
MX (1) MX2011008485A (ru)
NI (1) NI201100155A (ru)
NZ (1) NZ595046A (ru)
PE (1) PE20120791A1 (ru)
SG (2) SG10201609184PA (ru)
TN (1) TN2011000403A1 (ru)
TW (2) TW201034665A (ru)
UY (2) UY32444A (ru)
WO (2) WO2010093839A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20150111930A1 (en) * 2013-10-23 2015-04-23 Afgin Pharma, Llc Topical regional neuro-affective therapy
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
CN102442942A (zh) * 2010-10-08 2012-05-09 天津和美生物技术有限公司 4-氨基吡啶的多晶型物及其制备和应用
CA2825810A1 (en) * 2011-01-28 2012-08-02 Acorda Therapeutics, Inc. Use of 4-aminopyridine to treat cerebral palsy
EA201491522A1 (ru) * 2012-02-13 2014-12-30 Акорда Терапьютикс, Инк. Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
EP3103096A4 (en) * 2014-02-04 2018-01-03 Optimata Ltd. Method and system for prediction of medical treatment effect
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
WO2022124946A1 (ru) * 2020-12-10 2022-06-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение
CN112914884B (zh) * 2021-01-19 2022-02-11 重庆火后草科技有限公司 通过稳态时长置信度测量睡眠状态下的体重值的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе

Also Published As

Publication number Publication date
CA2751581A1 (en) 2010-08-19
BRPI1000030A2 (pt) 2018-02-14
NI201100155A (es) 2012-02-16
SG10201609184PA (en) 2016-12-29
CN102046174A (zh) 2011-05-04
NZ595046A (en) 2013-10-25
CL2011001927A1 (es) 2012-07-20
TN2011000403A1 (en) 2013-03-27
TW201032809A (en) 2010-09-16
PE20120791A1 (es) 2012-07-08
US20120029035A1 (en) 2012-02-02
SG173641A1 (en) 2011-09-29
WO2010093838A1 (en) 2010-08-19
AU2016219650C1 (en) 2018-08-23
TW201034665A (en) 2010-10-01
KR20170034452A (ko) 2017-03-28
UY32444A (es) 2010-09-30
UY32445A (es) 2010-09-30
BRPI1000031A2 (pt) 2018-02-14
KR20120000560A (ko) 2012-01-02
JP2012517449A (ja) 2012-08-02
EA022755B1 (ru) 2016-02-29
ECSP11011311A (es) 2011-10-31
US20150313886A1 (en) 2015-11-05
AU2016219650B2 (en) 2018-05-10
AU2010213663A1 (en) 2011-09-29
WO2010093839A1 (en) 2010-08-19
US20170319562A1 (en) 2017-11-09
AR075413A1 (es) 2011-03-30
CN101896182A (zh) 2010-11-24
CO6440534A2 (es) 2012-05-15
IL214500A0 (en) 2011-09-27
AU2016219650A1 (en) 2016-09-15
KR20180114250A (ko) 2018-10-17
MX2011008485A (es) 2011-11-04

Similar Documents

Publication Publication Date Title
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
SG194701A1 (en) Anti-cd40 antibodies and methods of use
EA201001639A1 (ru) Композиции и способы их получения и применения
UA122324C2 (uk) Терапевтично активні сполуки і способи їх застосування
NZ707086A (en) Anti-cd40 antibodies and methods of use
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
AU2011328009A8 (en) Compounds and methods for treating pain
EA201201357A1 (ru) Антитела к cd40
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
EA201101530A1 (ru) ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2014004862A (es) Formulaciones de polimero acrilico.
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
PH12015500746A1 (en) Benzamides
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
EA201270728A1 (ru) Пуриновые соединения
CL2009000949A1 (es) Compuestos derivados de 1,2,3,5-tetrahidro-indolizina, 6,7,8,9-tetrahidro-4h-quinolizina sustituidos, inhibidores de la actividad de cinasa de mek; su composicion farmaceutica; su uso para el tratamiento de enfermedades hiperproliferativas, tal como cancer e inflamaciones.
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea